David Schenkein compensation by year
AGIOS PHARMACEUTICALS Summary Compensation Table · all 4 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|
| Salary | $568,000 | $585,040 | $625,000 | $212,500 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $1,893,938 | $489,951 |
| Option awards | $2,582,051 | $4,921,476 | $5,160,125 | $1,840,179 |
| Non-equity incentive | $340,800 | $456,300 | $507,813 | $30,469 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $9,928 | $9,548 | $12,448 | $3,277 |
| Total | $3,500,779 | $5,972,364 | $8,199,324 | $2,576,376 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: AGIOS PHARMACEUTICALS, INC. DEF 14A filed April 16, 2020, accession 0001193125-20-109284, and prior-year filings. Open the filing on EDGAR.
How this page was built: the AGIOS PHARMACEUTICALS, INC. filed document, accession 0001193125-20-109284. Every figure is read from that document and cited to the page and table it appears in. Filed April 16, 2020.
Equity holdings
unvested awards at FY2019 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 16,250 | $775,938 | — |
| RSU | 8,324 | $397,471 | — |
| Option | 41,681 | — | $50.40 |
| Option | 52,815 | — | $77.70 |
| Option | 45,719 | — | $58.86 |
| Option | 4,250 | — | $39.76 |
Per the Outstanding Equity Awards at Fiscal Year-End table in AGIOS PHARMACEUTICALS, INC.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.
AGIOS PHARMACEUTICALS’s named executive officers, FY2019
as the company reported each| Named executive officer | Role | FY2019 total |
|---|---|---|
| Jacqualyn Fouse | Chief Executive Officer | $16,607,994 |
| Andrew Hirsch | Former Chief Financial Officer | $4,248,831 |
| Christopher Bowden | Former Chief Medical Officer | $3,227,208 |
| Jonathan Biller | Chief Legal Officer | $3,183,889 |
| David Schenkein · this page | Former President and Chief Executive Officer; Executive Chairman | $2,576,376 |
Board service
AGIOS PHARMACEUTICALS board · FY2021–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $9,424 | $0 | $0 | $0 | $9,424 |
| FY2024 | $57,500 | $89,994 | $266,287 | $0 | $413,781 |
| FY2023 | $57,500 | $89,985 | $269,767 | $0 | $417,252 |
| FY2022 | $72,500 | $89,997 | $269,800 | $0 | $432,297 |
| FY2021 | $87,500 | $89,965 | $269,983 | $0 | $447,447 |
Each year as the company reported it in AGIOS PHARMACEUTICALS's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: AGIOS PHARMACEUTICALS pays directors a $50,000 cash retainer and $400,000 in RSUs/Options. As stated in AGIOS PHARMACEUTICALS's FY2025 proxy.
The full AGIOS PHARMACEUTICALS compensation record
free company briefThis page is one person within AGIOS PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the AGIOS PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are AGIOS PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.